Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. - Wikidata - wikimedia - TriplyDB

Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.

Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.

http://www.wikidata.org/entity/Q34726423

about

Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus Cardiovascular effects of basal insulins Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care.A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.Current management of diabetes mellitus and future directions in care.The past, present, and future of basal insulins.Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes.[Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE].Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia.Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials.

P2860

Q26777076-E2564238-C0CC-483E-AC50-B47ED585754E Q26800249-212C945D-9C95-42AC-98E4-93441B20F0D0 Q31154873-9AEB6E8C-A06A-41B6-99FC-F880C9435507 Q35666228-E53D3D06-B489-4D6F-8ED7-29D5F772DB06 Q36467597-E59FC7ED-70EB-426A-B704-F7B870B0D36C Q36924024-08E51450-2CB2-40DF-B0FE-FA494A291CBA Q36971833-AB061225-9D9B-4FB8-8070-5E8A75487ED1 Q37227389-D17FFEAE-A02C-4153-8E91-EA33E77A2F46 Q37337304-25940F85-9A4E-4561-B403-BEA9727DA410 Q37737461-DDFB7DC7-9DDE-4C80-87C7-7B4DEE6F4DD9 Q38374615-72D239C5-D302-42FE-9BD0-38812C8F7A87 Q38470334-3A3AB1F0-85CC-490B-95F3-9452EF82B299 Q38570757-B90C810E-F857-49F3-948A-114C2268F419 Q38603504-F502D44E-6747-49D1-A189-5F75EFA61381 Q38618376-3ED664DB-437F-4144-B6EC-ABB8AF1989A8 Q38824504-5B6785B0-DA2A-4F0D-A03A-1C33A193889F Q39321463-A0AD67A1-FCD4-48A7-8323-C4045BBC957E Q39462093-78F07A20-BD16-4F6D-89E6-B01763D0DD2A Q42329441-4188C90A-357F-492B-9593-2776DCFE4E57 Q42371741-C5BAB70B-9799-4D9A-9674-4299A96D9A24 Q47136443-7D8A50BF-8312-4736-936B-1A3746743AA6 Q47429828-27047360-9ACC-4B3F-BC9B-A5714AFD11E5 Q47557627-1B51F3DC-D2E7-4D91-A41C-31AB04675E0B Q47927613-4970EC6E-CF2C-4E60-8C06-28786B6D37EA Q51130872-E0752A9B-71DD-493C-ABAE-BB0403962AC2 Q52611423-4E0CCCB5-157F-4873-85A8-C9B89E41B3FE Q52836101-19FD30F6-5633-4569-AA97-0F8A8D09E4B2 Q55262528-50B1D9B4-103D-4FBF-A9C4-C1D99EF7B60A Q55262674-DE97C425-81B2-4E5A-B63A-381EB20E896A

P2860

Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.

http://www.wikidata.org/entity/Q34726423

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Insulin degludec versus insuli ...... endpoints in phase 3a trials.

@ast

Insulin degludec versus insuli ...... endpoints in phase 3a trials.

@en

Insulin degludec versus insuli ...... endpoints in phase 3a trials.

@nl

type

label

Insulin degludec versus insuli ...... endpoints in phase 3a trials.

@ast

Insulin degludec versus insuli ...... endpoints in phase 3a trials.

@en

Insulin degludec versus insuli ...... endpoints in phase 3a trials.

@nl

prefLabel

Insulin degludec versus insuli ...... endpoints in phase 3a trials.

@ast

Insulin degludec versus insuli ...... endpoints in phase 3a trials.

@en

Insulin degludec versus insuli ...... endpoints in phase 3a trials.

@nl

P1433

Q34726423-36F56907-6730-4FA0-B2BB-FA082F8FF2E1

P1476

Q34726423-9BF15448-4690-4CD0-95A1-B1DA083B5FD1

P2093

Q34726423-02D78542-E6D1-46DC-AD9F-85753DDE189C

Q34726423-A6C95086-FC21-42B7-A82D-793DF27A51EF

Q34726423-AA869544-6F08-4910-97B1-39E841DA335E

Q34726423-E78FFD82-6AFF-4A46-8626-31998549442B

P2860

Q34726423-06C5B332-1BAC-4EDE-8C83-891679622C17

Q34726423-06F29EEE-BB21-43FD-A96B-5D2E95442228

Q34726423-0D5E097A-EE6B-4FB2-B677-20CE30E8CCBB

Q34726423-1093871B-4299-41D0-8C5F-620C3000E132

Q34726423-193E41B9-1BA3-496D-B38C-0B31B9B77173

Q34726423-24CD3C45-6820-43A6-9B63-1D846E4C4DCA

Q34726423-357EE9E8-6E58-4260-AB5F-734239CD3719

Q34726423-465C97EF-AD67-4DD3-9681-086437981B76

Q34726423-7DF1B5DC-E629-46A8-B0E7-911C5E3E35BB

Q34726423-8A3ACC31-7347-4694-8427-78141F117924

P2888

Q34726423-34DF198E-17C7-49D1-84CB-AB78160FD433

P304

Q34726423-7DE1AB9D-1C28-482C-A78A-8C57327C9FC2

P31

Q34726423-62EF255B-1E3E-4C4F-AE42-A2326CE6A7C5

P356

Q34726423-AC615879-E5E0-40AE-A7FA-99192D058A04

P433

Q34726423-61DFB04A-ECFE-4D5A-9081-9874F4A0C43D

P478

Q34726423-03DE37F2-57B9-48EF-93D1-7CDE5CF8039D

P577

Q34726423-662BA759-A3F4-4398-A70B-D75B59D097F4

P5875

Q34726423-204D9442-D5C1-45F5-8DB5-196E5AB565EF

P6179

Q34726423-379D40EF-2C47-4490-951A-90D2C3F82D3A

P698

Q34726423-EE990871-445A-4A0A-8AE2-26FDFA30EB6C

P921

Q34726423-65F3CA75-6415-49D0-AF65-EDAED59D63EE

Q34726423-9BD5417A-8995-4F46-9311-92E02CD6675E

Q34726423-9D4ACDC8-1392-43B3-A377-1B3F40B303E2

Q34726423-F5BF5600-E9B8-48D3-9C95-1A69B42C5766

P932

Q34726423-93727063-D3FE-42C1-A986-EA951D062FFF

P356

S13300-014-0076-9

P1433

Diabetes Therapy

P1476

Insulin degludec versus insuli ...... endpoints in phase 3a trials.

@en

P2093

Azhar Rana

http://www.w3.org/2001/XMLSchema#string

Jiten Vora

http://www.w3.org/2001/XMLSchema#string

Steve C Bain

http://www.w3.org/2001/XMLSchema#string

Torsten Christensen

http://www.w3.org/2001/XMLSchema#string

P2860

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes.

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

P2888

s13300-014-0076-9

P304

435-446

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-014-0076-9

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264433045

http://www.w3.org/2001/XMLSchema#string

P6179

1029423801

http://www.w3.org/2001/XMLSchema#string

P698

25081590

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

type-2 diabetes

P932

4269648

http://www.w3.org/2001/XMLSchema#string